文献速递产科母胎医学

妊娠期嗜铬细胞瘤/副神经节瘤:影响诊断与结局的临床线索系统综述

Pregnancy and phaeochromocytoma/paraganglioma: clinical clues affecting diagnosis and outcome - a systematic review.
PubMed 文献 · BJOG · 2021-01-25

该系统综述纳入1988年至2019年发表的204例妊娠期嗜铬细胞瘤/副神经节瘤病例报告,旨在明确产前与产后/死后诊断的临床线索。结果显示产后/死后诊断者孕产妇死亡率显著高于产前诊断者(29.3% vs 0.7%,调整OR 45.9),子代死亡率亦更高(OR 3.1)。高血压、出汗及已知PPGL病史/基因突变/肾上腺肿块是产前诊断的独立因素,而急性症状发作、初始诊断子痫前期等是产后诊断的独立因素。

要点

  • 产后/死后诊断PPGL的孕产妇死亡率是产前诊断的42倍(29.3% vs 0.7%)。
  • 高血压、出汗、已知PPGL病史/基因突变/肾上腺肿块提示产前诊断。
  • 急性症状发作、初始诊断子痫前期、因产科原因入院、母体心动过速提示产后诊断。

核心结论

  • 多个临床线索可帮助临床医生考虑妊娠期PPGL的产前诊断,从而可能改善结局。

研究设计与样本

  • 系统综述,检索1988年1月1日至2019年6月30日发表的英文、德文、荷兰文或法文妊娠期PPGL病例报告,纳入含预设最低临床数据的病例报告,由两名作者独立提取数据并评估质量,计算OR(95%CI)并进行单因素和多因素logistic回归分析。

主要发现

  • 孕产妇死亡率为9.0%(18/200),胎儿/新生儿死亡率为14.2%(29/204)。
  • 产后/死后诊断PPGL的孕产妇死亡率为29.3%(17/58),产前诊断为0.7%(1/142),调整OR 45.9(95%CI 5.67-370),P=0.0003。
  • 产后/死后诊断PPGL的子代死亡率是产前诊断的2.6倍(OR 3.1,95%CI 1.38-6.91,P=0.0044)。
  • 产前诊断的独立因素包括:入院时高血压(OR 2.29,95%CI 1.12-4.68,P=0.022)、出汗(OR 3.14,95%CI 1.29-7.63,P=0.014)、已知PPGL病史/基因突变/肾上腺肿块(OR 8.87,95%CI 1.89-41.64,P=0.0056)。
  • 产后诊断的独立因素包括:急性症状发作(OR 8.49,95%CI 3.52-20.5,P<0.0001)、初始诊断子痫前期(OR 6.34,95%CI 2.60-15.5,P<0.0001)、因产科原因入院(OR 10.71,95%CI 2.70-42.45,P=0.0007)、母体心动过速(OR 2.72,95%CI 1.26-5.85,P=0.011)。

临床怎么用

  • 对于妊娠期高血压、出汗或有PPGL病史/基因突变/肾上腺肿块的孕妇,应警惕PPGL并考虑产前筛查。
  • 对于急性症状发作、初始诊断子痫前期、因产科原因入院或心动过速的孕妇,需注意排除PPGL,避免漏诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phaeochromocytoma and paraganglioma (PPGL) in pregnancy, if not diagnosed antepartum, pose a high risk for mother and child. OBJECTIVE: To examine the clinical clues of antepartum and postpartum/postmortem diagnosis of PPGL. SEARCH STRATEGY: Case reports on PPGL in pregnancy published between 1 January 1988 and 30 June 2019 in English, German, Dutch or French. SELECTION CRITERIA: Case reports containing a predefined minimum of clinical data on PPGL and pregnancy. DATA COLLECTION AND ANALYSIS: Two authors independently performed data extraction and assessed data quality. We calculated odds ratios (OR) (with 95% confidence intervals) and used uni- and multivariable logistic regression analysis. MAIN RESULTS: Maternal and fetal/neonatal mortalities were 9.0% (18/200) and 14.2% (29/204), respectively. Maternal mortality was 42-fold higher with PPGL diagnosed postpartum/postmortem (17/58; 29.3%) than antepartum (1/142; 0.7%) (adjusted OR 45.9, 95% CI 5.67-370, P = 0.0003). Offspring mortality was 2.6-fold higher with PPGL diagnosed postpartum/postmortem than antepartum (OR 3.1, 95% CI 1.38-6.91, P = 0.0044). Hypertension at admission (OR 2.29, 95% CI 1.12-4.68, P = 0.022), sweating (OR 3.14, 95% CI 1.29-7.63, P = 0.014) and a history of PPGL, a known PPGL-associated gene mutation or adrenal mass (OR 8.87, 95% CI 1.89-41.64, P = 0.0056) were independent factors of antepartum diagnosis. Acute onset of symptoms (OR 8.49, 95% CI 3.52-20.5, P < 0.0001), initial diagnosis of pre-eclampsia (OR 6.34, 95% CI 2.60-15.5, P < 0.0001), admission for obstetric care (OR 10.71, 95% CI 2.70-42.45, P = 0.0007) and maternal tachycardia (OR 2.72, 95% CI 1.26-5.85, P = 0.011) were independent factors of postpartum diagnosis. CONCLUSION: Several clinical clues can assist clinicians in considering an antenatal diagnosis of PPGL in pregnancy, thus potentially improving outcome. TWEETABLE ABSTRACT: Systematic review of 204 pregnant patients with phaeochromocytoma identified clinical clues for a timely antepartum diagnosis.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Langton K, Tufton N, Akker S, et al. Pregnancy and phaeochromocytoma/paraganglioma: clinical clues affecting diagnosis and outcome - a systematic review. BJOG. 2021. PMID: 33342020. doi:10.1111/1471-0528.16635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。